In breast cancer, loss of PEDF correlated inversely with outcomes in patients, as re-expression of PEDF restored tamoxifen sensitivity in endocrine-resistant cancer cells, and loss of PEDF reduced tamoxifen sensitivity in endocrine-responsive cells [55]. This evidence concerns the gene SERPINF1 and cancer.